VGI Health Technology Limited
ABN: 35 111 082 485
Address: Level 45, MLC Centre, 19 Martin Place, Sydney NSW 2000
www.vgiht.com | Tel: +61 2 8279 8908
VGI Health Technology’s Dr Jordan Moon to current
at American Society for Nutrition Conference
Sydney New South Wales, 21 March 2022 – VGI Health Technology Limited (NSX:VTL) is happy to announce that Dr Jordan Moon, a member of its Scientific Advisory Board, shall be presenting an summary on the American Society for Nutrition (ASN) Annual Conference, Nutrition 2022. In 2028, the ASN shall be celebrating 100 years as a number one advocate for diet scientists and the development of diet. With 1000’s of members in over 100 international locations, ASN’s Nutrition 2022 is the perfect platform for Dr Moon to debate his work.
In affiliation with the ASN, an summary shall be offered throughout the convention (14-16 June 2022) titled “Transmucosal supply of tocotrienols from a delta-tocotrienolpowder: A Multidose Pharmacokinetic research“.
The summary describes a few of the outcomes which were generated from a pharmacokinetics research performed by Dr Moon within the US utilizing new formulations developed for the transmucosal supply of tocotrienols. These new formulations and strategies of manufacture are additionally the topic of a brand new patent submitting “PCT/AU2021/051449 – Transmucosal supply of tocotrienols” made by VTL’s wholly-owned subsidiary Invictus Biotechnology Pty Ltd on 3 December 2021. The information from this research helps the truth that there may be extra flexibility with dosages for this explicit drug supply platform than earlier analysis information had advised.
Sixteen wholesome analysis topics (m=8, f=8, 32 +/- 8 years, 171 +/- 7 cm, 81.6 +/- 13.8 kg) had been randomly administered both 40mg or 80mg of a delta tocotrienol (DT3) containing powder in a fasted state. Subjects had been requested to maintain the powder below their tongue till it was absolutely dissolved. Blood samples had been taken at 0, 60, 90, 120, 180, 240, 360, and 480 minutes. Subjects got a meal consisting of carbohydrates, proteins, and fat after 4 hours. DT3 concentrations had been calculated from blood plasma utilizing protein precipitation adopted by liquid-liquid extraction. Analytes had been separated by Liquid Chromatography Mass Spectrometry (LCMS) with the extracts assayed towards a calibration curve. DT3 bioavailability was assessed utilizing the parameters peak plasma focus (Cmax), time to succeed in peak plasma focus (Tmax) and complete space below the plasma concentration-time curve (AUC).
The plasma focus of DT3 reached 44.05 ng/ml (Cmax) for the 40mg group and reached
127.4 ng/ml (Cmax) (+83.4 ng/ml enhance) for the 80mg group. Tmax was achieved at 360 minutes for each the 40 and 80mg group. AUC for 40mg resulted in 9,941.6 ng/ml*min, with a +2.9 occasions enhance noticed within the 80mg group (29,072.2 ng/ml*min) in comparison with 40mg.
Transmucosal supply of tocotrienols from a delta-tocotrienol powder containing 40mg and 80mg of DT3 resulted in a progressively elevated absorption price for each doses with 80mg showing to extend complete plasma DT3 by a distinction of +2.9 occasions that of a 40mg dose. Both 40 and 80mg doses of DT3 administered by way of transmucosal supply have proven enhanced plasma DT3 concentrations in wholesome women and men over a interval of a minimum of 8 hours.